Acorda Therapeutics Inc (NASDAQ:ACOR)
| 32.60 Data as of 12:26pm ET |  +0.20 / +0.62%Today’s Change | 21.26 Today|||52-Week Range 40.87 | +31.13% Year-to-Date |
Latest ACOR News | Press Releases
No recent news for Acorda Therapeutics Inc.
Today’s Trading
| Previous close | 32.40 |
| Today’s open | 32.40 |
| Day’s range | 32.40 - 32.94 |
| Volume | 105,644 |
| Average volume (3 months) | 456,232 |
| Market cap | $1.3B |
| Dividend yield | -- |
Data as of 12:26pm ET, 05/22/2013
Growth & Valuation
| Earnings growth (last year) | +405.26% |
| Earnings growth (this year) | -90.88% |
| Earnings growth (next 5 years) | +24.50% |
| Revenue growth (last year) | +4.65% |
| P/E ratio | 9.0 |
| Price/Sales | 3.21 |
| Price/Book | 3.34 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VVUSVIVUS Inc | +0.23 | +1.75% |
| IPXLImpax Laboratories I... | +0.25 | +1.35% |
| NPSPNPS Pharmaceuticals ... | +1.20 | +8.26% |
| INFIInfinity Pharmaceuti... | -1.86 | -7.40% |
Data as of 12:46pm ET, 05/22/2013
Financials
| Next reporting date | August 6, 2013 |
| EPS forecast (this quarter) | $0.10 |
| Annual revenue (last year) | $305.8M |
| Annual profit (last year) | $155.0M |
| Net profit margin | 50.67% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Ronald Cohen, MD |
Chief Financial Officer David Lawrence, MBA |
Corporate headquarters Ardsley, New York |
Forecasts
